Literature DB >> 2591005

Herpes simplex virus, Candida albicans and mouth ulcers in neutropenic patients with non-haematological malignancy.

G Beattie1, J Whelan, J Cassidy, L Milne, S Burns, R Leonard.   

Abstract

Mouth ulcers are a frequent cause of morbidity in patients rendered neutropenic as a result of chemotherapy. We report here a series of 28 such patients from whom swabs were taken for viral isolation and mycological culture. In 13 patients, herpes simplex virus (type I) was isolated and in 17 patients Candida albicans was cultured. Both organisms were isolated in 9 patients. Our results suggest that both a viral and fungal element may be important in the aetiology of oral ulceration and that antiviral and antifungal agents may each have a role in the prophylaxis and treatment of such patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591005     DOI: 10.1007/bf00694344

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Virus infections in immunocompromised patients: their importance and their management.

Authors:  R N Sutton; R F Itzhaki; J Christophers; J Saldanha; A Gannicliffe; H Anderson
Journal:  J R Soc Med       Date:  1985-02       Impact factor: 5.344

Review 2.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

3.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

4.  Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study.

Authors:  M T Lam; G J Pazin; J A Armstrong; M Ho
Journal:  Cancer       Date:  1981-11-15       Impact factor: 6.860

5.  Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.

Authors:  H Anderson; J H Scarffe; R N Sutton; E Hickmott; D Brigden; C Burke
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

  5 in total
  6 in total

Review 1.  A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions.

Authors:  Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen
Journal:  Support Care Cancer       Date:  2016-11-16       Impact factor: 3.603

Review 2.  A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea.

Authors:  Sharon Elad; Yehuda Zadik; Ian Hewson; Allan Hovan; M Elvira P Correa; Richard Logan; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-06-11       Impact factor: 3.603

3.  Herpes simplex virus and oral mucositis in children with cancer.

Authors:  G Carrega; E Castagnola; A Canessa; P Argenta; R Haupt; G Dini; A Garaventa
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

4.  Role for macrophage inflammatory protein 2 (MIP-2), MIP-1alpha, and interleukin-1alpha in the delayed-type hypersensitivity response to viral antigen.

Authors:  Terrence M Tumpey; Robin Fenton; Sara Molesworth-Kenyon; John E Oakes; Robert N Lausch
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 5.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014

Review 6.  GINGIVAL ULCERATIONS IN A PATIENT WITH ACUTE MYELOID LEUKEMIA: A case report and literature review.

Authors:  Vanja Vučićević Boras; Danica Vidović Juras; Igor Aurer; Sandra Bašić-Kinda; Mirta Mikulić
Journal:  Acta Clin Croat       Date:  2019-09       Impact factor: 0.780

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.